Jochen Hammes1, Alexander Drzezga2,3, Thilo van Eimeren2,3,4. 1. Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany. jochen.hammes@uk-koeln.de. 2. Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany. 3. German Center for Neurodegeneration (DZNE), Bonn, Germany. 4. INM-3, Research Center Jülich, Jülich, Germany.
Abstract
PURPOSE OF REVIEW: Differential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases. RECENT FINDINGS: Several tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing. A combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS.
PURPOSE OF REVIEW: Differential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases. RECENT FINDINGS: Several tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing. A combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS.
Entities:
Keywords:
Atypical Parkinson syndromes; Flortaucipir; PBB3; THK-5351; Tau PET
Authors: Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Christine Ghadery; Jinhee Kim; Anthony E Lang; Sylvain Houle; Antonio P Strafella Journal: Brain Struct Funct Date: 2017-09-07 Impact factor: 3.270
Authors: Daniel R Schonhaut; Corey T McMillan; Salvatore Spina; Bradford C Dickerson; Andrew Siderowf; Michael D Devous; Richard Tsai; Joseph Winer; David S Russell; Irene Litvan; Erik D Roberson; William W Seeley; Lea T Grinberg; Joel H Kramer; Bruce L Miller; Peter Pressman; Ilya Nasrallah; Suzanne L Baker; Stephen N Gomperts; Keith A Johnson; Murray Grossman; William J Jagust; Adam L Boxer; Gil D Rabinovici Journal: Ann Neurol Date: 2017-10 Impact factor: 10.422
Authors: Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson Journal: Neurology Date: 2017-07-28 Impact factor: 9.910
Authors: Michelle T Fodero-Tavoletti; Shozo Furumoto; Leanne Taylor; Catriona A McLean; Rachel S Mulligan; Ian Birchall; Ryuichi Harada; Colin L Masters; Kazuhiko Yanai; Yukitsuka Kudo; Christopher C Rowe; Nobuyuki Okamura; Victor L Villemagne Journal: Alzheimers Res Ther Date: 2014-02-26 Impact factor: 6.982
Authors: Matthias Brendel; Sonja Schönecker; Günter Höglinger; Simon Lindner; Joachim Havla; Janusch Blautzik; Julia Sauerbeck; Guido Rohrer; Christian Zach; Franziska Vettermann; Anthony E Lang; Lawrence Golbe; Georg Nübling; Peter Bartenstein; Katsutoshi Furukawa; Aiko Ishiki; Kai Bötzel; Adrian Danek; Nobuyuki Okamura; Johannes Levin; Axel Rominger Journal: Front Aging Neurosci Date: 2018-01-17 Impact factor: 5.750